Læs hele analysen af Novo Nordisk her.
Bull og Bear scenarier:
Bulls say
- The increased prevalence of obesity and pateint conversion to pricier modern insulin offerings should expand the branded diabetes-care market by 12% anually over the next five years.
- With a promising pipeline full of nextgeneration insulins, Novo is well positioned to defend its formidable diabetes market share in the long run.
- Novo's prowess developing therapeutic proteins has led to the creation of a highly profitable line of biopharmaceutical products for hemophilia and other disorders, helping to diversify its top line and further boost margins.
Bears Say
- Tresiba, Ryzodeg, and Xultophy won't reach the lucrative U.S. market until at least 2016, allowing Sanofi to continue to dominate with Lantus and introduce new insulin offering Toujeo in the interim.
- Novo and its insulin market peers have enjoyed tremendous U.S. pricing power in recent years, but the passing of the patent cliff and increased consolidation of PBMs could limit this power in the future.
- Novo's Victoza has been a strong growth driver, but exclusion from the Express Scripts formulary in 2014 and the introduction of other potent GLP-1 analogs could weigh on growth.
©2014 Morningstar. All rights reserved. The information, data, analyses, and opinions contained herein (1) are proprietary to Morningstar, Inc. and its affiliates (collectively, “Morningstar”), (2) may not be copied or redistributed, (3) do not constitute investment advice offered by Morningstar (4) are provided solely for informational purposes and therefore are not an offer to buy or sell a security, and (5) are not warranted to be accurate, complete, or timely. Certain information may be self-reported by the investment vehicle and not subject to independent verification. Morningstar shall not be responsible for any trading decisions, damages, or other losses resulting from, or related to, this information, data, analyses or opinions or their use. Past performance is no guarantee of future results.